Michał Wszoła, CEOBased in European Union, the scientific and technological innovator creates functional tissue models and organ prototypes designed for human transplants. Its innovations are leading to the societal transformation of medicine, elevating biotechnology and 3D bioprinting from services to civilizational milestones.
“We are pushing the boundaries of what’s biologically and clinically possible, offering new solutions where conventional medicine has reached its limits,” says Michał Wszoła, CEO.
Polbionica’s flagship achievement is the world’s first fully functional Bionic Pancreas—ATMP (Advanced Therapy Medicinal Product). The living, bioprinted organ with functional vasculature can produce insulin and glucagon, offering a groundbreaking therapeutic solution for brittle, complicated diabetes and chronic pancreatitis. Sized like a natural pancreas and designed for minimally invasive transplantation, the Bionic Pancreas-ATMP restores metabolic control, reduces pain, cancer risk, and helps patients regain independence while lowering healthcare costs.
Polbionica is preparing to complete the first-in-human clinical trial of its bioprinted pancreas. Classified as an ATMP in Europe and a biologic combination product in the U.S., the trial is scheduled for late 2026.
“The development of the Bionic Pancreas demonstrates how multiple technologies create an ecosystem that enables breakthrough innovations. Biocompatible bioinks, UV crosslinking systems, the Flow&Culture™ bioreactor for automated, perfusable, sterile culturing and research on 3D bioprinted structures (organoids, tissues, organs), and hybrid recombinant proteins come together to form the OrganoBionica™ platform,” adds Maciej Szurek – CCO.
It advances Polbionica’s mission to develop scientific alternatives to animal testing—marking a critical ethical and scientific milestone. It also helps overcome five key hurdles in preclinical R&D: low translational relevance, lack of vascular precision, high R&D costs, slow innovation timelines and regulatory complexity.
Transforming Organ Engineering
The Bionic Pancreas is bioprinted using proprietary, fully biocompatible nextgeneration bioinks. Tailored for specific cell types and tissue functions, all bioinks are produced under rigorous ISO 13485 quality management standards. These bioinks span four core biomaterial domains, each designed to meet distinct research and clinical needs. Expert support is available to tailor formulations for specific applications.
The Flow&Culture bioreactor addresses the challenge of keeping the bioprinted tissues alive and functional. By providing automated feeding, sterile environment and continuous perfusion and precise control of temperature, flow, pressure, and gas levels, it creates a near-physiological environment that sustains tissue viability and function over extended periods.
This capability was crucial for a client assessing bioproduct degradation during in vitro perfusion. Using the Flow&Culture bioreactor, it continuously monitored biomaterials for up to three months, collecting robust data. This significantly reduced reliance on animal testing, streamlined bioethical approvals and accelerated their regulatory pathway.
We are pushing the boundaries of what’s biologically and clinically possible, offering new solutions where conventional medicine has reached its limits
This capability was crucial for a client assessing bioproduct degradation during in vitro perfusion. Using the Flow&Culture bioreactor, it continuously monitored biomaterials for up to three months, collecting robust data. This significantly reduced reliance on animal testing, streamlined bioethical approvals and accelerated their regulatory pathway.
In a subsequent use case, a client needed a reliable human liver metastatic carcinoma model to test immune-targeting drugs, an area where traditional humanized mouse models proved costly and inconsistent. Using Polbionica’s bioreactors and bioprinted models, the client received actionable results within three months and has since integrated these systems into its ongoing research pipeline.
For clients new to bioprinting and organoid fabrication, Polbionica offers comprehensive services from project design and implementation of bioprinting technologies to drug toxicity and efficacy testing and advanced cancer modeling for research and translational applications.
Regenerative Medicine for Tomorrow’s Healthcare
Behind Polbionica’s cutting-edge technologies and patents is a passionate team that believes medicine can be reimagined. Focused on social change, they redefine patients as active partners in the innovation process and work with doctors, scientists and medical institutions to shape the future of treatment.
To support innovations, Polbionica plans to open a GLPaligned innovation center in Boston focused on bioprinting tissue models and testing biologically active compounds. It is also broadening applications of its recombinant proteins, Silkistin and Reselastin, into skincare, hair care and orthopedic therapies for both human and veterinary applications. As it continues to scale its global footprint, it is exploring an IPO, with timing and listing venue to be shaped by strategic partnerships and evolving market conditions.
Polbionica’s breakthroughs in bioprinting and regenerative medicine are only the foundation of a broader vision to transform patient care, diagnosis and the future of medicine.
What Sets the Gold Standard in Bioprinting Solutions
Biotechnology companies are beginning to view bioprinting very differently from how they did even a few years ago. What was once treated largely as an experimental laboratory capability is increasingly being evaluated as a serious research and translational platform. That shift is being driven by practical challenges across drug development. Animal models often fail to predict human response accurately, traditional 2D assays oversimplify biological behavior and development programs continue to absorb significant capital before researchers gain meaningful clinical insight. At the same time, regulatory and scientific expectations around data quality are becoming more demanding. For executives responsible for research strategy, the question is no longer whether 3D tissue models are scientifically interesting. It is whether the technology is mature and reliable enough to improve decision-making in drug discovery, toxicity testing, regenerative medicine and personalized research.
Biological relevance remains the most important factor. Human-cell models, organoids and tissue constructs only create value when they reproduce meaningful biological behavior rather than simply resembling tissue visually. That places greater importance on factors such as vascularization, cell compatibility, extracellular-matrix support and long-term tissue viability. Platforms capable of sustaining tissue over extended periods can give research teams a clearer understanding of drug response, degradation patterns, immune activity and disease progression. For many organizations, the goal is not just reducing reliance on animal testing, but replacing weak predictive models with systems that generate more clinically relevant data earlier in development.
Consistency is equally important. Many bioprinting initiatives struggle because the workflow itself becomes fragmented. Researchers may rely on separate suppliers for bioinks, printing systems, perfusion technologies and culture environments, creating technical variability that is difficult to standardize across studies. Companies evaluating providers should look for partners that understand the entire process, from construct design and biomaterials through culture maintenance and functional analysis. The strongest solutions tend to be those that integrate materials, architecture and environmental controls in a way that improves repeatability and allows findings to transfer more easily into broader internal research programs.
Regulatory and quality considerations are also becoming more central as bioprinting moves closer to applied biomedical use. Sophisticated tissue models lose much of their value if they cannot support documentation standards, reproducibility requirements or partner-facing research expectations. Organizations working toward FDA, EMA or collaborative development programs increasingly need platforms developed with traceability, process control and long-term usability in mind. In practice, that means providers need to contribute scientific guidance as well as technical products. For teams working with biologically active compounds or complex disease environments, expertise in model design can become just as important as the materials themselves.
Polbionica has developed an approach that reflects many of these industry needs. Its platform combines proprietary bioinks such as TintBionic®, PrinTiss® and CleanCure™ with the ResearchLine™ Bioreactor designed for dynamic culture of tissue models and bionic constructs. The company’s work involving perfusable organoids, vascularized tissue models, recombinant proteins and bionic pancreas development suggests a level of depth that goes beyond supplying standalone materials. For biotechnology organizations focused on improving human-relevant testing, building reproducible culture systems and supporting more rigorous translational research, Polbionica offers a well-aligned and technically mature option.
...Read more
3D Bioprinting Solutions Info
Q1
Why is Polbionica recognized among top 3D Bioprinting Solutions providers?
Polbionica has gained international recognition in 3D Bioprinting Solutions through its pioneering work on a fully vascularized bionic pancreas developed for patients with type 1 diabetes and chronic pancreatitis. The company combines biotechnology, biomaterials engineering and regenerative medicine expertise to advance clinically relevant bioprinting applications rather than limiting its work to laboratory-scale experimentation. Its successful preclinical studies and preparation for clinical trials reflect a strong translational focus that positions the company at the forefront of organ biofabrication research. Polbionica also strengthens its standing through proprietary technologies including bioinks, bioreactors and tissue engineering platforms designed to support long-term medical innovation.
Q2
What differentiates Polbionica in the field of 3D bioprinting?
Advanced organ biofabrication capabilities distinguish Polbionica from many companies operating in 3D Bioprinting Solutions. Its research team developed one of the world’s first functional bionic pancreas prototypes with integrated vasculature, demonstrating a level of complexity rarely achieved in tissue engineering. The company also develops enabling technologies that support broader bioprinting applications, including the ResearchLine™ bioreactor and proprietary bioinks such as TintBionic®, CleanCure™ and Printiss®. This integrated ecosystem allows Polbionica to support both therapeutic development and research-focused applications while maintaining close alignment between biological performance and manufacturing precision.
Q3
How does Polbionica support innovation in regenerative medicine and transplantation research?
Scientific advancement remains central to Polbionica’s work across regenerative medicine and transplantation technologies. Through its 3D Bioprinting Solutions, the company develops bioprinted organs, organoids, tissue models and biomaterials intended for transplantology, drug discovery and preclinical research. Its multidisciplinary team includes physicians, engineers, biotechnologists and laboratory specialists who collaborate across scientific and clinical disciplines to move research toward practical healthcare applications. The company’s continued investment in biofabrication technologies helps address global challenges related to organ shortages while supporting the development of more advanced tissue engineering methods.
Q4
How do Polbionica’s technologies create value for healthcare and research organizations?
Reliable biological performance and scalable research tools are critical in modern tissue engineering. Polbionica delivers value through 3D Bioprinting Solutions that support both therapeutic development and advanced biomedical research. Its proprietary bioinks and bioreactor technologies help researchers create more stable and biologically relevant tissue structures for experimentation and clinical investigation. The company also focuses on compliance with international quality standards, including ISO 13485 certification, which reinforces confidence in its development and manufacturing processes. This combination of scientific innovation and structured quality management allows Polbionica to support healthcare institutions and research organizations pursuing next-generation regenerative therapies.
Q5
What role do quality standards and technical expertise play in Polbionica’s approach?
Strong quality control systems support every stage of Polbionica’s product development strategy. The company operates under an ISO 13485-compliant quality management framework designed for medical devices and advanced therapy medicinal products. Within the 3D Bioprinting Solutions sector, this level of regulatory alignment demonstrates a commitment to safety, effectiveness and process reliability. Polbionica combines that quality discipline with deep technical expertise in biomaterials, software development and tissue engineering, allowing it to manage highly specialized research while preparing technologies for future clinical application. Its interdisciplinary structure also encourages collaboration between scientific research and commercial development activities.
Q6
Why is Polbionica relevant to the future of biomedical technology?
Demand for advanced regenerative therapies continues to grow as healthcare systems search for alternatives to traditional transplantation methods. Polbionica addresses this need through 3D Bioprinting Solutions focused on functional organ development and personalized tissue engineering technologies. Its long-term vision centers on introducing bioprinted organs into routine clinical practice while improving outcomes for patients affected by chronic diseases such as type 1 diabetes. The company’s combination of scientific research, proprietary materials technology and clinical preparation work reflects a forward-looking approach that aligns closely with the future direction of regenerative medicine and biofabrication.
